Cupps Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Cupps Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,432	Closed	-$463K	–	225
2015 Q4	$463K	Buy	+2,432	New	+$425K	0.06%	130
2015 Q1	–	Sell	-1,695	Closed	-$313K	–	238
2014 Q4	$313K	Sell	1,695 -600	-26%	-$111K	0.03%	168
2014 Q3	$380K	Buy	2,295 +835	+57%	+$137K	0.04%	163
2014 Q2	$228K	Buy	+1,460	New	+$231K	0.02%	167

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Cupps Capital Management's ALXN Position: Q1 2016 in Review

Cupps Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 2,432 shares — an estimated $463K sold.

Cupps Capital Management first reported a position in ALXN in Q2 2014 and held it in 4 quarters. The position peaked at $463K in Q4 2015. 520 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Cupps Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Cupps Capital Management sold 2,432 Alexion Pharmaceuticals shares in Q1 2016, an estimated $463K.
Cupps Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 4 quarters.
Cupps Capital Management's Alexion Pharmaceuticals position peaked at $463K in Q4 2015.
520 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Cupps Capital Management's 13F filing for Q1 2016, filed 12 May 2016.